82
Participants
Start Date
April 19, 2023
Primary Completion Date
February 28, 2026
Study Completion Date
February 29, 2036
Cessation of anti-HER2 treatment
Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
University of Pittsburgh Medical Center, Pittsburgh
Duke University, Durham
Mayo Clinical Hospital Florida, Jacksonville
Mayo Clinic Rochester, Rochester
Baylor College of Medicine, Houston
Mayo Clinic Hospital Arizona, Phoenix
Fred Hutchinson Cancer Center, Seattle
Georgetown University Medical Center, Washington D.C.
Dana-Farber Cancer Insitute, Boston
DFCI @ Foxborough, Foxborough
DFCI @ Merrimack Valley, Methuen
DFCI @ Milford Regional Hospital, Milford
DFCI @ South Shore Hospital, South Weymouth
National Cancer Institute (NCI)
NIH
Gateway for Cancer Research
OTHER
Susan G. Komen Breast Cancer Foundation
OTHER
Translational Breast Cancer Research Consortium
OTHER
Johns Hopkins University
OTHER
Dana-Farber Cancer Institute
OTHER